Laser for melasma sounds more decisive than it usually is.
The evidence says something narrower: laser or light procedures can improve melasma scores in selected patients when added to topical therapy, but they can also trigger redness and post-inflammatory hyperpigmentation. In the 2026 systematic review, 11 randomized trials included 461 people. There was no significant benefit at 4 weeks, improvement appeared by 8, 12, and 16 weeks, and adverse events were more likely in the combination group, mainly erythema and PIH. [1]
That makes laser a candidacy question, not a shortcut. After menopause, the better sequence is diagnosis first, then trigger control, topical plan, visible-light protection, PIH-risk review, and only then procedure selection.
Diagnosis comes before the device
Melasma is usually symmetric brown or gray-brown facial pigmentation, but not every brown patch is melasma. American Academy of Dermatology says a dermatologist can often diagnose melasma by looking closely at the face and neck, may use a Wood's lamp or dermatoscope to see how deeply pigment reaches, and may perform a skin biopsy when melasma could be another condition. [2]
That matters before a procedure. Treating the wrong pigment problem can delay care or worsen discoloration.
| Pigment pattern | Why it may look like melasma | Why diagnosis matters before laser |
|---|---|---|
| Melasma | Symmetric brown or gray-brown facial patches, often on sun-exposed areas. [2] | Laser may be an add-on only after topical and photoprotection basics are in place. |
| Post-inflammatory hyperpigmentation | Darkening after acne, irritation, burns, procedures, rash, or injury. | A procedure that inflames the skin can worsen pigment-prone skin. [1] |
| Lentigines or sun damage | Brown spots after cumulative UV exposure, common in midlife. | Spot treatments differ from melasma treatment and may need dermoscopy. |
| Actinic keratosis or other sun-damage lesion | Rough, scaly, or changing areas can coexist with pigment. | These need lesion evaluation, not melasma-lightening treatment. |
| Changing, bleeding, irregular, multicolor, or asymmetric lesion | Can be mistaken for cosmetic pigment early. | American Academy of Dermatology's ABCDE warning signs mean this should be checked before cosmetic treatment. [7] |
The key question is not "Which laser removes pigment?" It is "What pigment diagnosis are we treating?"
What the 2026 laser evidence actually says
The strongest recent evidence is careful but not definitive. The 2026 meta-analysis reviewed laser or light-based therapy plus topical agents versus topical agents alone. The pooled result favored combination therapy by 8 to 16 weeks, but the safety signal moved in the wrong direction. [1]
| Finding from the 2026 review | What it means for the decision |
|---|---|
| 11 randomized controlled trials, 461 people | Useful evidence, but still modest when split across devices, settings, skin types, and topical combinations. [1] |
| No significant benefit at 4 weeks | Expecting a fast one-session fix is the wrong expectation. [1] |
| Significant improvement at 8, 12, and 16 weeks | Benefit may be cumulative when combined with topical therapy. [1] |
| Pooled SMD -0.55, 95% confidence interval -0.74 to -0.36 | The combined approach improved melasma severity scores versus topical therapy alone. [1] |
| Adverse-event odds ratio 8.96, 95% confidence interval 3.71 to 21.64 | Side effects were substantially more likely in the combination group. [1] |
| Main adverse events were erythema and PIH | The exact problem the patient wants treated can get worse if inflammation is triggered. [1] |
| Evidence certainty was moderate for efficacy and very low for safety | The benefit signal is more reliable than the safety estimate. [1] |
That is why the best answer is not "laser yes" or "laser no." The evidence is limited and mixed enough that laser should fit only when the risk profile, skin type, diagnosis, device, settings, topical plan, and maintenance plan make sense.
PIH risk changes who fits
Post-inflammatory hyperpigmentation risk is the central decision point. Melasma is pigment-prone by definition, and procedures work partly by controlled injury, heat, or light interaction. If the skin responds to inflammation by darkening, a procedure can trade one pigment problem for another.
American Academy of Dermatology says a melasma treatment plan should consider skin tone, how deeply pigment reaches, and triggers such as sunlight, medicines, and stress. It also says there is no one best treatment; effective plans often combine sun protection, topical medications, and sometimes a procedure. [2]
| Factor | Lower-risk direction | Higher-risk direction |
|---|---|---|
| Diagnosis | Confirmed melasma after dermatology review. | Unclear pigment, changing lesion, rough lesion, or suspected PIH from irritation. |
| Prior PIH history | Little history of darkening after acne, burns, peels, lasers, waxing, or irritation. | Dark marks after minor inflammation or prior procedures. |
| Skin tone and reaction pattern | Device and settings selected for the patient's skin and pigment depth. [2] | Generic settings or discount-device treatment without skin-tone planning. |
| Topical foundation | Stable topical regimen and sun protection already in place. | Procedure-first plan with no maintenance. |
| Expectations | Improvement and relapse reduction are the goal. | "Cure" or single-session removal is the expectation. |
| Operator | Board-certified dermatologist or supervised dermatology procedure setting. [2] | Unclear training, no diagnosis, no stop rules, no adverse-event plan. |
The more risk factors are in the right column, the less laser should be the next step.
Photoprotection is still treatment, not aftercare
Visible light matters in melasma. In a double-blind randomized trial, 68 patients were assigned to UV plus visible-light sunscreen or UV-only sunscreen, and both groups used 4% hydroquinone. Sixty-one patients completed the 8-week study. The UV plus visible-light group showed 15% greater improvement in MASI, 28% greater improvement in colorimetric values, and 4% greater improvement in melanin assessment than the UV-only group. [4]
American Academy of Dermatology similarly tells patients with melasma that dermatologists often recommend sunscreen containing zinc oxide, titanium dioxide, and iron oxide. [2]
| Foundation step | Why it matters before laser |
|---|---|
| Broad-spectrum sunscreen plus visible-light protection | Helps reduce a major trigger and supports relapse prevention. [2] [4] |
| Tinted sunscreen with iron oxide | Can protect against visible light and reduce white cast. [2] [4] |
| Topical therapy | American Academy of Dermatology lists hydroquinone, tretinoin/corticosteroid combinations, triple-combination cream, azelaic acid, kojic acid, and vitamin C as options clinicians may use. [2] |
| Trigger review | Sunlight, medications, and stress can trigger melasma; unresolved triggers can erase procedure gains. [2] |
| Maintenance plan | Cochrane found treatment evidence heterogeneous and called for better long-term outcomes, which is why relapse planning matters. [3] |
For many patients, the highest-return improvement is not a stronger device. It is doing the foundation plan consistently enough that a procedure has a lower chance of backfiring.
How laser compares with other treatment categories
Melasma care is a sequence, not a ladder where every patient eventually gets laser. Topicals, photoprotection, oral or topical tranexamic acid, chemical peels, microneedling, and laser/light procedures carry different evidence and safety questions.
| Option | Best-fit role | Evidence or safety boundary |
|---|---|---|
| Hydroquinone or triple-combination topical therapy | Common prescription foundation for many patients. | Cochrane found triple-combination cream outperformed hydroquinone alone in included studies, but overall evidence was heterogeneous. [3] |
| Azelaic acid | Alternative or adjunct when hydroquinone is not a fit. | A 2023 meta-analysis found azelaic acid may reduce MASI more than hydroquinone in included randomized controlled trials, but larger long-term studies are needed. [5] |
| Tranexamic acid | Refractory melasma discussion, especially oral TXA in selected patients. | The 2023 review notes oral TXA can be effective but pro-thrombotic risk must be considered. [6] |
| Chemical peel or microneedling | Selected procedural adjuncts. | American Academy of Dermatology lists them as procedures dermatologists may add, but selection and skin-tone planning matter. [2] |
| Laser or light treatment | Dermatologist-led add-on after diagnosis, topicals, and photoprotection. | 2026 review showed benefit by 8 to 16 weeks but more adverse events, mainly erythema and PIH. [1] |
This framing helps avoid a common trap: comparing a procedure's best-case before-and-after photos against a topical plan's real-world maintenance job.
What to ask your clinician before saying yes
- Is this definitely melasma, or could it be PIH, lentigines, actinic damage, medication pigment, or a lesion that needs dermoscopy or biopsy?
- What is my PIH risk based on skin tone, prior dark marks, acne marks, peel reactions, burn reactions, and prior device history?
- Which device, wavelength, fluence, pulse duration, endpoint, and number of sessions are being proposed?
- What topical prep and visible-light sunscreen plan should be stable before treatment?
- What improvement should we expect at 8, 12, and 16 weeks, and what would count as failure or worsening?
- What redness, burning, blistering, darkening, crusting, or uneven pigment should trigger a recheck?
- What maintenance plan prevents relapse after the procedure series ends?
Bottom line
Laser for melasma after menopause is not a cure-first decision. It is a risk-selected add-on.
Start with diagnosis, visible-light protection, topical treatment, trigger review, and a PIH-risk discussion. If those are solid, laser or light therapy may fit as a dermatologist-led procedure. If the diagnosis is unclear, the skin tends to darken after irritation, or the plan skips maintenance, the procedure can create the exact problem it is trying to fix.
Related reading:
- Melasma After Menopause Treatment Options.
- Tinted Sunscreen for Melasma After Menopause.
- Hydroquinone and Tri-Luma for Melasma After Menopause.
- Tranexamic Acid for Melasma After Menopause.
- Chemical Peels After Menopause.
- Actinic Keratosis After Menopause.
References
[1] Fithria RF, Supranoto YTN, Liu Z, Peng J. Laser and light-based therapies combined with topical agents for melasma: A systematic review and meta-analysis. Medicine (Baltimore). 2026;105(2):e46579. doi:10.1097/md.0000000000046579 https://pubmed.ncbi.nlm.nih.gov/41517728/
[2] American Academy of Dermatology. Melasma: Diagnosis and treatment. https://www.aad.org/public/diseases/a-z/melasma-treatment
[3] Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010;2010(7):CD003583. doi:10.1002/14651858.cd003583.pub2 https://pubmed.ncbi.nlm.nih.gov/20614435/
[4] Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, Fuentes-Ahumada C, Torres-Álvarez B. Near-visible light and UV photoprotection in the treatment of melasma: a double-blind randomized trial. Photodermatol Photoimmunol Photomed. 2014;30(1):35-42. doi:10.1111/phpp.12086 https://pubmed.ncbi.nlm.nih.gov/24313385/
[5] Albzea W, AlRashidi R, Alkandari D, et al. Azelaic Acid Versus Hydroquinone for Managing Patients With Melasma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus. 2023;15(7):e41796. doi:10.7759/cureus.41796 https://pubmed.ncbi.nlm.nih.gov/37457606/
[6] Konisky H, Balazic E, Jaller JA, Khanna U, Kobets K. Tranexamic acid in melasma: A focused review on drug administration routes. J Cosmet Dermatol. 2023;22(4):1197-1206. doi:10.1111/jocd.15589 https://pubmed.ncbi.nlm.nih.gov/36606378/
[7] American Academy of Dermatology. What to look for: ABCDEs of melanoma. https://www.aad.org/public/diseases/skin-cancer/find/at-risk/abcdes